Strive, a Nasdaq-listed asset manager, purchased 3,311 Bitcoin between October 5 and 9 at an average price of about $84,500 per coin, spending roughly $280 million in its largest single purchase since January. This acquisition increased Strive's total Bitcoin holdings to 32,773 BTC, valued at approximately $2.73 billion. The purchase comes after earlier buys of $169 million and $94.5 million in Bitcoin, reflecting an aggressive accumulation strategy during a recent dip in Bitcoin prices. Strive's move highlights a growing trend among public companies to build Bitcoin treasury reserves, though it carries risks due to Bitcoin's volatility.
Strive's recent $280 million Bitcoin purchase provides context for cryptocurrency market activity. For readers following crypto, here is Pluang's market snapshot as of Oct 14, 2026 01:03 WIB: out of 50 major cryptocurrencies, 13 rose and 36 fell. Notable movers include ZIL at Rp61 with a 1-day change of -4.71%, ALGO at Rp2.137 down 4.43%, and DOT at Rp20.771 down 4.31%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
